Oculis Holding AG
CHFinancials
Valuation Metrics
Oculis Holding AG's Market Cap is $603M. At end of 2025 it was $1.07B. Ranked #2723 of 3,121 in US market (top 87%), #1175 of 1,463 on NASDAQ (top 80%), #216 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $603M | US#2,723/3,121 Sec#216/266 |
| Revenue | $607889.00 | US#2,878/3,121 Sec#192/266 |
| Net Income | $-115M | US—/3,121 Sec—/266 |
| Total Assets | $307M | US#2,909/3,121 Sec#206/266 |
| Net Assets | $248M | US#2,603/3,121 Sec#171/266 |
| Employees | 60 | US#2,697/3,121 Sec#204/266 |
| Value | ||
| P/B | 2.43x | US#1,507/3,121 Sec#67/266 |
| P/S | 991.42x | US#2,989/3,121 Sec#198/266 |
| FCF Yield | -12.64% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -46.30% | US#2,664/3,121 Sec#150/266 |
| ROA | -37.31% | US#2,934/3,121 Sec#181/266 |
| Op. Margin | -16740.95% | US#2,877/3,121 Sec#190/266 |
| Financial Health | ||
| Debt Ratio | 24.08% | US#269/3,121 Sec#91/266 |
| Total Debt | $3M | US#2,950/3,121 Sec#231/266 |
| FCF | $-76M | US#2,588/3,121 Sec#130/266 |
| Cash | $81M | US#2,343/3,121 Sec#190/266 |
| Current Ratio | 5.18x | US#457/3,121 Sec#139/266 |
| Performance | ||
| 1Y Return | -42.64% | US#2,825/3,121 Sec#239/266 |
| 1M Return | -24.34% | US#3,035/3,121 Sec#251/266 |
| From 52W High | -71.06% | US#3,026/3,121 Sec#244/266 |
| 1Y MDD | -69.65% | US#2,953/3,121 Sec#238/266 |
| Trading | ||
| Volume | 246,354 shares | US#2,527/3,121 Sec#246/266 |
| Trading Value | $2M | US#2,862/3,121 Sec#242/266 |
| Per Share | ||
| EPS | $-1.90 | US—/3,121 Sec—/266 |
| BPS | $4.10 | US#2,354/3,121 Sec#138/266 |
Company Info
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.